VAPO News and Press, Vapotherm Inc. From 07/29/22

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings for companies due to report...

Gainers: GeoVax Labs ( GOVX ) +42% . InflaRx ( IFRX ) +37% . Sunshine Biopharma ( SBFM ) +35% . Nutriband ( NTRB ) +29% . Talaris Therapeutics ( TALS ) +24% . Chimerix ( CMRX ) +20% . Liberty TripAdvisor Holdings ...

Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy ® products which are used to treat patients of all ag...

I list and explain ten factors for choosing stocks to go long and ten factors for choosing stocks to short or buy puts on. These are factors I use every day, and include earnings growth, share turnover, free cash flow, and many others. At the end of the article I list my top ten s...

Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages ...

Vapotherm has seen a boom induced by the pandemic reverse violently. The pandemic has not boosted Vapotherm's business, as losses have only increased during this period of time. With revenues down to much lower levels and losses being very substantial, there are no (quick) fixes i...

Vapotherm, Inc. (VAPO) Q1 2022 Earnings Conference Call May 04, 2022, 16:30 ET Company Participants Mark Klausner - Westwicke Partners Joseph Army - CEO, President & Director John Landry - SVP, CFO & Treasurer Conference Call Participants Brandon Vazquez - William Blair & Company ...

Canaccord Genuity has downgraded Vapotherm (NYSE:VAPO) to hold from buy saying that comments from management during its recent earnings call position the company for transition over the next couple of years. The firm also dropped its price target to $5 from $12 (~12% upside based on Thursday'...

Vapotherm press release (NYSE:VAPO): Q1 GAAP EPS of -$0.87 misses by $0.22. Revenue of $21.62M beats by $0.59M. FY22 net revenue is expected to be in the range of $81M-$86M For further details see: Vapotherm GAAP EPS of -$0.87 misses by $0.22, revenue of $21.62M beats by $0.59M

Revenue of $21.6 Million In-Line with Preliminary Revenue of $20.5 Million to $21.5 Million Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced first quarter 2022 financial results. First Quarter 2022 Summary ...